bioAffinity Technologies, Inc. Announces CyPath® Lung Test Featured at Cleveland Clinic Symposium

bioAffinity Technologies, Inc. announced that its CyPath® Lung test will be featured at the invitation-only “Advances in Early Lung Cancer Detection” symposium at the Cleveland Clinic on April 16, 2026. The symposium focuses on early lung cancer detection and brings together global leaders in the field. Dr. Gordon Downie, Chief Medical Officer of bioAffinity Technologies, will participate in a panel discussion on lung nodule management, highlighting the benefits of CyPath® Lung in aiding early detection in high-risk patients. The test, which uses flow cytometry and AI to analyze sputum, has shown potential in detecting cancer at Stage 1A and can help avoid unnecessary invasive procedures. This marks bioAffinity Technologies' seventh invitation to present at this event, underscoring the continued interest in their diagnostic solutions for lung cancer.